EMPLOYMENT AGREEMENTEmployment Agreement • August 14th, 2003 • Corautus Genetics Inc • Biological products, (no disgnostic substances) • Georgia
THIS EMPLOYMENT AGREEMENT (the “Agreement”), effective as of February 5, 2003 (the “Effective Date”), between ROBERT T. ATWOOD (the “Executive”) and CORAUTUS GENETICS INC., a Delaware corporation (the “Company”);
INVESTMENT AGREEMENTInvestment Agreement • August 14th, 2003 • Corautus Genetics Inc • Biological products, (no disgnostic substances) • New York
INVESTMENT AGREEMENT, dated as of July 30, 2003 (the “Signing Date”), between CORAUTUS GENETICS INC., a Delaware corporation (the “Company”), and BOSTON SCIENTIFIC CORPORATION, a Delaware corporation (the “Investor”, each a “Party” and together with the Company, the “Parties”).
April 15, 2003 Carin Sandvik 1473 Flair Encinitas Drive Encinitas, CA 92024 Re: Retention Arrangement Dear Carin:Corautus Genetics Inc • August 14th, 2003 • Biological products, (no disgnostic substances) • California
On behalf Corautus Genetics Inc. (the “Company”), I am pleased to provide you with this letter agreement (“Agreement”) setting forth the various terms and conditions of a retention arrangement which the Company is offering you in the context of the current reduction in force. This Agreement will be effective immediately upon the date the Company timely receives a copy executed by you as indicated below (the “Effective Time”) and, of course, will be null and void if you fail to return such a copy as specified below. As explained herein, although you will remain an “at-will” employee, the Company has agreed to pay you certain bonuses for remaining employed through a specified date.
LOAN AGREEMENT among BOSTON SCIENTIFIC CORPORATION as Purchaser, and CORAUTUS GENETICS INC. and VASCULAR GENETICS INC. as Issuers Dated as of July 30, 2003Loan Agreement • August 14th, 2003 • Corautus Genetics Inc • Biological products, (no disgnostic substances) • New York
LOAN AGREEMENT (this “Agreement”) is made and entered into this 30th day of July, 2003, among CORAUTUS GENETICS INC., a Delaware corporation (“Parent”), and its wholly-owned subsidiary, VASCULAR GENETICS INC., a Delaware corporation (“VGI” and, together with the Parent, the “Issuers”), and BOSTON SCIENTIFIC CORPORATION, a Delaware corporation (the “Purchaser” and, together with the Issuers, the “Parties”).
DEVELOPMENT AGREEMENT by and between BOSTON SCIENTIFIC CORPORATION and CORAUTUS GENETICS INC. Dated as of July 30, 2003Development Agreement • August 14th, 2003 • Corautus Genetics Inc • Biological products, (no disgnostic substances) • New York
This DEVELOPMENT AGREEMENT (this “Agreement“) is made and entered into this 30th day of July, 2003 (the “Effective Date”) by and between BOSTON SCIENTIFIC CORPORATION (“BSC”), a Delaware corporation, and CORAUTUS GENETICS INC. (the “Company”), a Delaware corporation (each a “Party,” and collectively, the “Parties”).
DISTRIBUTION AGREEMENT by and between BOSTON SCIENTIFIC CORPORATION and CORAUTUS GENETICS INC. Dated as of July 30, 2003Distribution Agreement • August 14th, 2003 • Corautus Genetics Inc • Biological products, (no disgnostic substances) • New York
This DISTRIBUTION AGREEMENT (this “Agreement”) is made and entered into this 30th day of July, 2003 (the “Effective Date”) by and between BOSTON SCIENTIFIC CORPORATION (“BSC”), a Delaware corporation, and CORAUTUS GENETICS INC. (the “Company”), a Delaware corporation (each a “Party,” and collectively, the “Parties”).
INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • August 14th, 2003 • Corautus Genetics Inc • Biological products, (no disgnostic substances) • New York
INVESTOR RIGHTS AGREEMENT, dated as of July 30, 2003, between Corautus Genetics Inc., a Delaware corporation (the “Company”), and BOSTON SCIENTIFIC CORPORATION, a Delaware corporation (the “Investor”).
